福安药业
(300194)
| 流通市值：42.90亿 | | | 总市值：52.70亿 |
| 流通股本：9.68亿 | | | 总股本：11.90亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 920,507,640.79 | 467,678,211.11 | 2,391,468,105.37 | 1,995,281,936.35 |
| 营业收入 | 920,507,640.79 | 467,678,211.11 | 2,391,468,105.37 | 1,995,281,936.35 |
| 二、营业总成本 | 859,575,205.52 | 424,656,082.74 | 2,124,236,673.71 | 1,733,508,475.64 |
| 营业成本 | 578,672,967.4 | 277,152,681 | 1,124,997,486.04 | 938,496,920.59 |
| 税金及附加 | 12,978,822.67 | 6,468,368 | 30,752,914.2 | 23,427,541.74 |
| 销售费用 | 99,536,304.86 | 58,120,765.7 | 563,426,225.62 | 492,031,678.93 |
| 管理费用 | 107,398,617.59 | 53,478,613.35 | 258,776,299.62 | 189,140,117.54 |
| 研发费用 | 62,513,285.14 | 30,330,798.21 | 153,223,657.68 | 95,368,357.23 |
| 财务费用 | -1,524,792.14 | -895,143.52 | -6,939,909.45 | -4,956,140.39 |
| 其中:利息费用 | 11,295,353.72 | 1,919,204.41 | 23,338,101.62 | 18,092,076.42 |
| 其中:利息收入 | 12,652,690.37 | 6,155,799.35 | 29,808,752.85 | 23,170,390.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 444,849.31 | 60,712.33 | -32,735,646.45 | 13,465.75 |
| 加:投资收益 | 60,523,130.09 | 30,950,153.11 | 76,987,951.6 | 54,150,158.46 |
| 资产处置收益 | -35,989.89 | 0 | 9,036.8 | 231,063.13 |
| 资产减值损失(新) | -9,449,459.93 | -3,192,658.29 | -34,741,850.61 | -11,796,662.05 |
| 信用减值损失(新) | -7,090,729.23 | -3,842,431.67 | -3,792,040.34 | 4,992,614.01 |
| 其他收益 | 14,462,727.55 | 6,157,771.01 | 47,887,951.1 | 37,850,621.28 |
| 四、营业利润 | 119,786,963.17 | 73,155,674.86 | 320,846,833.76 | 347,214,721.29 |
| 加:营业外收入 | 534,005.62 | 132,705.57 | 4,697,109.41 | 1,723,006.51 |
| 减:营业外支出 | 1,910,362.12 | 800,760.47 | 13,347,389.08 | 6,231,263.62 |
| 五、利润总额 | 118,410,606.67 | 72,487,619.96 | 312,196,554.09 | 342,706,464.18 |
| 减:所得税费用 | 5,669,049.53 | 3,689,880.99 | 34,025,539.11 | 40,787,400.46 |
| 六、净利润 | 112,741,557.14 | 68,797,738.97 | 278,171,014.98 | 301,919,063.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 112,741,557.14 | 68,797,738.97 | 278,171,014.98 | 301,919,063.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 113,120,774.38 | 69,049,030.79 | 279,837,280.89 | 301,606,802.14 |
| 少数股东损益 | -379,217.24 | -251,291.82 | -1,666,265.91 | 312,261.58 |
| 扣除非经常损益后的净利润 | 104,050,392.23 | 65,684,805.91 | 258,500,650.37 | 282,994,529.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.06 | 0.24 | 0.25 |
| (二)稀释每股收益 | 0.1 | 0.06 | 0.24 | 0.25 |
| 八、其他综合收益 | -16,143,070.73 | -21,233,854.46 | 30,781,583.67 | 11,273,867.2 |
| 归属于母公司股东的其他综合收益 | -16,143,070.73 | -21,233,854.46 | 30,781,583.67 | 11,273,867.2 |
| 九、综合收益总额 | 96,598,486.41 | 47,563,884.51 | 308,952,598.65 | 313,192,930.92 |
| 归属于母公司股东的综合收益总额 | 96,977,703.65 | 47,815,176.33 | 310,618,864.56 | 312,880,669.34 |
| 归属于少数股东的综合收益总额 | -379,217.24 | -251,291.82 | -1,666,265.91 | 312,261.58 |
| 公告日期 | 2025-08-27 | 2025-04-24 | 2025-04-24 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |